Multiple financial and investment groups have recently adjusted their holdings in Boston Scientific Corporation ($BSX), with several decreasing and many increasing their stake. Renowned firms like Aberdeen Group plc, Callan Family Office LLC, Eastern Bank, and Shell Asset Management Co. have all grown their position in BSX. This is in line with a positive sentiment from analysts, affirmed by RBC Capital and Jefferies maintaining a 'Buy' on the stock, along with Piper Sandler and Oppenheimer reaffirming their positive stance. The stock faced a drop of 10.3% in the previous four weeks but analysts are optimistic about its future performance. Boston Scientific's innovation pipeline is being considered to counterbalance its market execution strategies. This follows its announcement for Q2 2025 results and subsequent stock rise. Despite recent declines, Boston Scientific Corporation is highly regarded as a top growth stock for the long-term. The corporation has also secured FDA labeling expansion for its FARAPULSE Pulsed Field Ablation (PFA) System.
Boston Scientific Corp BSX News Analytics from Sat, 19 Apr 2025 07:00:00 GMT to Sat, 11 Oct 2025 10:38:10 GMT - Rating 5 - Innovation 7 - Information 2 - Rumor -6
